Tag: NCT03189719

Home / NCT03189719

Categories

Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer

August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for pati...
nct03189719

Scan the code